BRPI1010639A2 - sistema farmacêutico para distribuição transmembrana - Google Patents

sistema farmacêutico para distribuição transmembrana

Info

Publication number
BRPI1010639A2
BRPI1010639A2 BRPI1010639A BRPI1010639A BRPI1010639A2 BR PI1010639 A2 BRPI1010639 A2 BR PI1010639A2 BR PI1010639 A BRPI1010639 A BR PI1010639A BR PI1010639 A BRPI1010639 A BR PI1010639A BR PI1010639 A2 BRPI1010639 A2 BR PI1010639A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical system
transmembrane
distribution
transmembrane distribution
pharmaceutical
Prior art date
Application number
BRPI1010639A
Other languages
English (en)
Inventor
David R Carver
Sean William Reynolds
Troy Fohrman
Original Assignee
Protein Delivery Solutions Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Delivery Solutions Llc filed Critical Protein Delivery Solutions Llc
Publication of BRPI1010639A2 publication Critical patent/BRPI1010639A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
BRPI1010639A 2009-05-13 2010-05-12 sistema farmacêutico para distribuição transmembrana BRPI1010639A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17775309P 2009-05-13 2009-05-13
US24333809P 2009-09-17 2009-09-17
PCT/US2010/034606 WO2010132605A1 (en) 2009-05-13 2010-05-12 Pharmaceutical system for trans-membrane delivery

Publications (1)

Publication Number Publication Date
BRPI1010639A2 true BRPI1010639A2 (pt) 2016-03-15

Family

ID=42590948

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010639A BRPI1010639A2 (pt) 2009-05-13 2010-05-12 sistema farmacêutico para distribuição transmembrana

Country Status (13)

Country Link
US (1) US20100291160A1 (pt)
EP (1) EP2429503A1 (pt)
JP (1) JP2012526840A (pt)
CN (1) CN102421420A (pt)
AU (1) AU2010249047A1 (pt)
BR (1) BRPI1010639A2 (pt)
CA (1) CA2763368A1 (pt)
IL (1) IL216306A0 (pt)
MX (1) MX2011012043A (pt)
RU (1) RU2011150521A (pt)
SG (1) SG176000A1 (pt)
TW (1) TW201043280A (pt)
WO (1) WO2010132605A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481275B (zh) 2009-06-24 2014-07-23 战略科学技术有限公司 含有布洛芬的表面组合物
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
EP2658551B1 (en) 2010-12-29 2020-07-01 Strategic Science & Technologies, LLC Treatment of erectile dysfunction and other indications
WO2012150707A1 (ja) * 2011-05-02 2012-11-08 国立大学法人熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法
JP5967675B2 (ja) * 2011-08-31 2016-08-10 ケーシーアイ ライセンシング インコーポレイテッド 減圧治療および創面切除用のシステムおよび方法
ME02153B (me) 2011-09-19 2015-10-20 Orexo Ab Nove farmaceutske kompozicije, otporne na zloupotrebu, za tretman zavisnosti od opioida
HRP20161634T1 (hr) 2012-05-02 2017-01-13 Orexo Ab Novi pripravak alfentanila za liječenje akutne boli
EP2968124A1 (en) * 2013-03-15 2016-01-20 Strategic Science & Technologies, LLC Transdermal formulations of fluticasone
CA2888219C (en) * 2014-02-07 2018-07-10 Scilabs Pharmaceuticals, Inc. All natural, non-toxic sublingual drug delivery systems
BR112016022293A2 (pt) 2014-03-28 2017-08-15 Galderma Res & Dev Composição que contém peróxido de benzoíla, uso cosmético de uma composição, medicamento destinado a uma aplicação tópica sobre a pele, kit e processo de preparação de uma composição autoespumante
FR3041535B1 (fr) 2015-09-29 2019-01-25 Galderma Research & Development Mousse chimique non rincee contenant du trifarotene, et son utilisation dans le traitement de l'ichtyose.
FR3041536B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant du trifarotene, et son utilisation dans le traitement de l'acne.
FR3041537B1 (fr) * 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant de la brimonidine et son utilisation dans le traitement de la rosacee.
FR3041539B1 (fr) * 2015-09-29 2018-10-26 Galderma Research & Development Composition nettoyante auto-moussante contenant du propionate de clobetasol, et son utilisation dans le traitement du psoriasis.
FR3041541B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee comprenant de l'ivermectine
FR3041538B1 (fr) * 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant du propionate de clobetasol, et son utilisation dans le traitement du psoriasis.
WO2017062985A1 (en) * 2015-10-09 2017-04-13 Children's National Medical Center Apparatus and method for physiologic and pharmacodynamic assessment and monitoring
CN108697637A (zh) * 2016-01-27 2018-10-23 因斯塔尔科技股份公司 用于治疗性处理的口腔粘膜纳米纤维载体
EP3866774B1 (en) * 2018-10-19 2026-01-28 Nova Southeastern University Sublingual epinephrine compositions including ph-modifying excipients and penetration enhancers and methods for use thereof
JP2021147362A (ja) * 2020-03-23 2021-09-27 学校法人常翔学園 舌下投与用ゼリー剤
CN113943352B (zh) * 2021-12-20 2022-03-29 浙江湃肽生物有限公司深圳分公司 一种纯化醋酸布雷默浪丹的方法
CN116869932A (zh) * 2023-08-25 2023-10-13 南京海科瑞医药科技有限公司 一种盐酸拉贝洛尔注射液及其制备方法

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
US5122127A (en) * 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
US5380758A (en) * 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5385937A (en) * 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia
US5725234A (en) * 1995-10-24 1998-03-10 Colibert; Floyd A. Ball-type coupler for trailers and the like
US6045788A (en) * 1996-02-28 2000-04-04 Cornell Research Foundation, Inc. Method of stimulation of immune response with low doses of IL-2
US5741500A (en) * 1996-07-15 1998-04-21 Yates; Alayne Gum growth pad
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US6140475A (en) * 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
WO1999001579A1 (en) * 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6221378B1 (en) * 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
JP4726296B2 (ja) * 1998-02-27 2011-07-20 インスティチュート ストローマン アーゲー 創傷治癒のためのマトリックスタンパク質組成物
US6113932A (en) * 1998-03-02 2000-09-05 Children's Hospital Medical Center Nontoxic vernix compositions and method of producing
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US20050147690A1 (en) * 1998-09-25 2005-07-07 Masters David B. Biocompatible protein particles, particle devices and methods thereof
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6436367B1 (en) * 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6271200B1 (en) * 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
DE60042057D1 (de) * 1999-01-29 2009-06-04 Esperanza Peptide Ltd Bukkales verabreichungssystem für proteinhaltige medikamente
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20040072765A1 (en) * 1999-04-28 2004-04-15 Novogen Research Pty Ltd. Cardiovascular and bone treatment using isoflavones
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US20030059376A1 (en) * 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
WO2001013957A2 (en) * 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
AU1437601A (en) * 1999-10-26 2001-05-08 Genometrix Genomics Incorporated A storage card for hosting a biological specimen
US6992081B2 (en) * 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
AU2001261744A1 (en) * 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
AU2001275032A1 (en) * 2000-06-01 2001-12-11 The Wistar Institute Of Anatomy And Biology Methods for detecting dna damage and screening for cancer therapeutics
CA2410680A1 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
IL155204A0 (en) * 2000-10-02 2003-11-23 Arizeke Pharmaceuticals Inc Compositions and methods for the transport of biologically active agents across cellular barriers
JP4822652B2 (ja) * 2000-11-22 2011-11-24 エンド ファーマシューティカルズ インコーポレイテッド 粘膜炎の治療
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US6544497B2 (en) * 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6485707B2 (en) * 2001-02-15 2002-11-26 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
WO2002067995A1 (en) * 2001-02-26 2002-09-06 Council Of Scientific And Industrial Research Carrier systems comprising vitamin b12 - biodegradable micro particulate conju gates for peroral delivery of drugs, peptides/proteins and vaccines
US20030017150A1 (en) * 2001-03-14 2003-01-23 Torphy Theodore J. Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses
CA2441454A1 (en) * 2001-03-14 2002-09-19 Avigen, Inc. Recombinant adeno-associated virus-mediated gene transfer via retroductal infusion of virions
WO2002074916A2 (en) * 2001-03-16 2002-09-26 Centocor, Inc. Reg-like protein immunoglobulin derived proteins, compositions, methods and uses
WO2002097048A2 (en) * 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
WO2003000236A1 (en) * 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc Particles with improved solubilization capacity
WO2003022910A1 (en) * 2001-09-08 2003-03-20 Access Pharmaceuticals, Inc. Synthesis and uses of polymer gel nanoparticle networks
US20040023338A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
AU2002365269A1 (en) * 2001-10-26 2003-07-24 Centocor, Inc. Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
JP2005512522A (ja) * 2001-10-26 2005-05-12 セントカー・インコーポレーテツド Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用
WO2003040304A2 (en) * 2001-11-09 2003-05-15 Neuronova Ab Method of proliferation in neurogenic regions
GB0130789D0 (en) * 2001-12-21 2002-02-06 King S College London Application of spores
US20060280761A1 (en) * 2002-03-11 2006-12-14 Health Plus International, Inc. Nanofluidized B-12 composition and process for treating pernicious anemia
US20040018195A1 (en) * 2002-03-26 2004-01-29 Griswold Don Edgar Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
WO2003092716A2 (en) * 2002-05-03 2003-11-13 Neuronova Ab Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
AU2003233119A1 (en) * 2002-05-08 2003-11-11 Neuronova Ab Modulation of neural stem cells with s1p or lpa receptor agonists
US6945952B2 (en) * 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
JP2006512051A (ja) * 2002-06-27 2006-04-13 セントカー・インコーポレーテツド Ｃｎｇｈ０００５ポリペプチド、抗体、組成物、方法および使用
EP1578930A4 (en) * 2002-06-27 2008-07-02 Centocor Inc CNGH0004 POLYPEPTIDES, ANTIBODIES, COMPOSITIONS, METHODS AND USES
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
KR20050073445A (ko) * 2002-08-14 2005-07-13 이 아이 듀폰 디 네모아 앤드 캄파니 코팅된 다가불포화 지방산 함유 입자 및 코팅된 액상 제약함유 입자
EP1393710A1 (en) * 2002-08-21 2004-03-03 The Procter & Gamble Company A method of applying an oral composition
US20040116370A1 (en) * 2002-08-30 2004-06-17 Genteric, Inc. Retroductal salivary gland genetic vaccination
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2004083902A2 (en) * 2002-10-25 2004-09-30 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
US20040122065A1 (en) * 2002-11-12 2004-06-24 Lerner E. Itzhak Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or buccally
US20050009847A1 (en) * 2002-11-20 2005-01-13 Goran Bertilsson Compounds and methods for increasing neurogenesis
US20040157330A1 (en) * 2003-01-09 2004-08-12 Arizeke Pharmaceuticals, Inc. Compositions and methods for targeted biological delivery of molecular carriers
US20050013854A1 (en) * 2003-04-09 2005-01-20 Mannino Raphael J. Novel encochleation methods, cochleates and methods of use
WO2004098502A2 (en) * 2003-04-30 2004-11-18 Centocor, Inc. Cngh0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses.
EP1623011B1 (en) * 2003-05-09 2013-01-02 Janssen Biotech, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
EP1644416A4 (en) * 2003-06-30 2007-08-29 Centocor Inc ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
US8075919B2 (en) * 2003-07-18 2011-12-13 Baxter International Inc. Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
WO2005034852A2 (en) * 2003-08-26 2005-04-21 Gel-Del Technologies, Inc. Protein biomaterials and biocoacervates and methods of making and using thereof
US20050136103A1 (en) * 2003-09-17 2005-06-23 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US20060127404A1 (en) * 2003-09-30 2006-06-15 Chichi Huang Hinge core mimetibodies, compositions, methods and uses
EP1692260A2 (en) * 2003-10-06 2006-08-23 Centocor, Inc. Hypoxia - responsive human cngh-0002 genes and polypeptides
EP1685107B1 (en) * 2003-11-03 2008-09-10 Myogen, Inc. 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
WO2005042487A1 (en) * 2003-11-03 2005-05-12 Myogen, Inc. 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
US20060182742A1 (en) * 2004-08-24 2006-08-17 Ishikawa Muriel Y System and method for magnifying a humoral immune response
EP1750754A4 (en) * 2004-03-31 2010-09-22 Centocor Ortho Biotech Inc HUMAN GLP-1 MIMETIC BODIES, COMPOSITIONS, METHODS AND USES
JP2007533755A (ja) * 2004-04-20 2007-11-22 ザ ユニヴァーシティ オヴ シカゴ 高分子量ｐｅｇ様化合物を含む治療薬送達システム
US20060020043A1 (en) * 2004-07-26 2006-01-26 Roger Berlin Methods and compositions for reducing C-reactive protein
US20060034889A1 (en) * 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20060110390A1 (en) * 2004-08-25 2006-05-25 Myogen, Inc. Inhibition of Ku as a treatment for cardiovascular diseases
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
US20060062758A1 (en) * 2004-09-21 2006-03-23 Nastech Pharmaceutical Comapny Inc. Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
JP5276982B2 (ja) * 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
US20070077283A1 (en) * 2005-09-30 2007-04-05 Nastech Pharmaceutical Company Inc. Method of enhancing transmucosal delivery of therapeutic compounds
WO2007056511A2 (en) * 2005-11-09 2007-05-18 Ontherix, Inc. Metal-binding therapeutic peptides
US7202229B1 (en) * 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
KR100784485B1 (ko) * 2006-01-18 2007-12-11 한국과학기술연구원 생분해성 온도 감응성 폴리포스파젠계 하이드로젤, 그의제조방법 및 그의 용도
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
US20100040609A1 (en) * 2006-07-07 2010-02-18 Gorman James R Methods for preventing, postponing or improving the outcome of invasive spinal procedures
KR20090039787A (ko) * 2006-07-18 2009-04-22 센토코 인코포레이티드 인간 ｇｌｐ-1 모방체, 조성물, 방법 및 용도
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
MX2009003376A (es) * 2006-09-28 2009-04-08 Bayer Consumer Care Ag Mezcla de sales de hierro y cobre que enmascaran el sabor metalico.
US20080103116A1 (en) * 2006-11-01 2008-05-01 Jennings-Spring Barbara L Method of treatment and compositions of D-chiro inositol and phosphates thereof
JP2010533205A (ja) * 2007-07-12 2010-10-21 トラガラ ファーマシューティカルズ，インク． 癌、腫瘍、および腫瘍関連障害を治療するための方法および組成物
MX2010004265A (es) * 2007-10-19 2010-07-28 Innozen Inc Composicion para administrar un ingrediente activo y metodo para hacer y usar el mismo.

Also Published As

Publication number Publication date
WO2010132605A1 (en) 2010-11-18
SG176000A1 (en) 2011-12-29
TW201043280A (en) 2010-12-16
MX2011012043A (es) 2012-03-29
JP2012526840A (ja) 2012-11-01
CN102421420A (zh) 2012-04-18
US20100291160A1 (en) 2010-11-18
EP2429503A1 (en) 2012-03-21
AU2010249047A1 (en) 2011-11-24
IL216306A0 (en) 2012-01-31
RU2011150521A (ru) 2013-06-20
CA2763368A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
DK2398500T3 (da) Glutathion-baseret lægemiddelafgivelsessystem
BRPI1006922A2 (pt) sistema para descarte de medicação
BRPI1012190A2 (pt) sistema de dispensação de produto
BRPI1012304A2 (pt) sistema para auxílio de subida
DK2506820T3 (da) Integreret hændelsesmarkersystem med farmaceutisk produkt til indtagelse
BRPI1010217A2 (pt) sistema
BR112014002554A2 (pt) sistema de dispensação
BR112013008625A8 (pt) sistema de iluminação de fundo para um monitor
BR112013011930A2 (pt) sistema para a determinação da qualidade da estrutura óssea de um indivíduo
BRPI0816730A2 (pt) sistema de distribuição de produto
BR112014009975A2 (pt) sistema proprietário de dispensação
ES1145834Y (es) Sistema de impresion para imprimir tejido
BR112014003134A2 (pt) sistema de dispensação
IL216306A0 (en) Pharmaceutical system for trans-membrane delivery
BR112013011955A2 (pt) sistema de distribuição de anúncio
BR112013011645A2 (pt) sistema de recirculação para chuveiro
BR112013015068A2 (pt) sistema de distribuição de produto,
BRPI1006691A2 (pt) sistema
IT1398480B1 (it) Sistema microfluidico
BR112012032131A2 (pt) sistema de banheiro para cachorros
CO7000753A2 (es) Sistema de cerchas
BR112012031789A2 (pt) sistema de toalete para cães
BRPI1014417A2 (pt) sistema
BR112012000445A2 (pt) sistema portatil para emergencias respiratorias
CO7020911A2 (es) Sistema para la administración de fármacos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]